New insider activity at Teva Pharmaceutical ( (TEVA) ) has taken place on February 15, 2025.
Discover the Best Stocks and Maximize Your Portfolio:
- See what stocks are receiving strong buy ratings from top-rated analysts.
- Filter, analyze, and streamline your search for investment opportunities with TipRanks’ Stock Screener.
EVP of International Markets Commercial, Mark Sabag, has recently executed a significant transaction involving Teva Pharmaceutical stock. He sold a total of 177,626 shares, amounting to a substantial $2,886,422.
Recent Updates on TEVA stock
Teva Pharmaceutical has recently reported its Q4 earnings, highlighting strong performance in its key product lines, particularly AUSTEDO, UZEDY, and AJOVY, which showed significant revenue growth. Despite the positive outlook, Teva is facing challenges such as macroeconomic pressures and potential revenue declines, especially concerning the anticipated drop in Revlimid revenue. The company’s strategic response includes the launch of new products to offset these declines. Analysts have adjusted their price targets for Teva, with UBS citing a “somewhat unfair” pullback and optimism for margin expansion in 2026, while Barclays points to “muted” 2025 EBITDA guidance and limited near-term catalysts as reasons for their adjustments. Teva’s stock has experienced notable declines, attributed to post-earnings reactions and ongoing market dynamics. Despite these challenges, Teva remains optimistic about its growth strategies and financial health, as reflected in its improved credit ratings and guidance for continued revenue growth.
More about Teva Pharmaceutical
YTD Price Performance: -21.92%
Average Trading Volume: 11,641,997
Technical Sentiment Consensus Rating: Hold
Current Market Cap: $18.92B